资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 从基金十大重仓股角度 数据显示，红塔红土基金旗下1只基金重仓悦康药业。红塔红土医药精选股票发起式A（020331）三季 度持有股数2.3万股，占基金净值比例为3.82%，位居第十大重仓股。根据测算，今日浮盈赚取约3.24万 元。 红塔红土医药精选股票发起式A（020331）成立日期2024年4月2日，最新规模1254万 ...

Core Viewpoint - The antibacterial drug market in China is under pressure, with sales expected to drop below 100 billion yuan in 2024 and continue declining by approximately 18% in the first three quarters of 2025, reaching over 60 billion yuan [1][14]. Market Performance - The total sales of systemic antibacterial drugs in public medical institutions in China have been declining, with a significant drop in sales from 2024 to 2025 [1][14]. - The market for systemic antibacterial drugs includes 12 major therapeutic categories, with cephalosporins leading but experiencing four consecutive years of sales decline from 2022 to the first three quarters of 2025 [3][16]. Company Rankings - In the ranking of major companies, Pfizer, China National Pharmaceutical Group, and North China Pharmaceutical Group hold the top three positions, with sales exceeding 6.2 billion yuan, 2.1 billion yuan, and 1.9 billion yuan respectively in the first three quarters of 2025 [5][18]. - Nanjing Youke Biological, ranked fifteenth, showed remarkable growth with a year-on-year increase of 137.17%, marking its first entry into the top 20 groups [5][18]. Product Performance - The top 20 systemic antibacterial drugs accounted for over 50% of the market share, with the leading product, injectable cefoperazone/sulbactam (2:1), achieving sales of over 4.5 billion yuan [21][22]. - Notably, the compound injection of cefoperazone/sulbactam saw a dramatic increase of 219.32%, marking a significant rise in its market presence [21][23]. National Procurement Impact - Among the top 20 products, 15 have been included in the national procurement program, with 13 experiencing double-digit declines in sales [21][23]. - The tenth batch of national procurement saw injectable piperacillin/tazobactam drop by 55.61%, while the eleventh batch saw injectable cefoperazone/sulbactam decline by 47.56% [21][23]. New Drug Development - Currently, there are no domestic class 1 new drugs among the top 20 systemic antibacterial products, although five class 1 new antibacterial drugs have been approved since 2021 [25][26]. - Eight products meet the criteria for national procurement inclusion, with seven being injectable forms and one oral formulation [25][26].

格隆汇12月29日丨白云山(600332.SH)公布，公司分公司广州白云山医药集团股份有限公司白云山制药 总厂（称"白云山制药总厂"） 收到国家药品监督管理局签发的《药品补充申请批准通知书》。药品通 用名称：注射用头孢呋辛钠，头孢呋辛钠为第二代头孢菌素，对大多数革兰氏阴性菌、革兰氏阳性菌敏 感，具有抗菌谱广、肾脏毒性较低、对β内酰胺酶稳定的优势，临床广泛用于治疗呼吸道感染、泌尿系 统感染及外科感染。 财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：钟离 ...

头孢呋辛钠为第二代头孢菌素，对大多数革兰氏阴性菌、革兰氏阳性菌敏感，具有抗菌谱广、肾脏毒性 较低、对β内酰胺酶稳定的优势，临床广泛用于治疗唿吸道感染、泌尿系统感染及外科感染。注射用头 孢呋辛钠被列入国家基本药物目录(2018)，属于国家医保乙类品种(2025)。 智通财经APP讯，白云山(00874)公布，近日，公司分公司广州白云山医药集团股份有限公司白云山制药 总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》。 白云山制药总厂注射用头孢呋辛钠于 2006 年 5 月在国内正式上市，并于 2025 年 4 月 3 日向国家药品监 督管理局递交一致性评价申请，于 2025 年 4 月 11 日获得受理。 白云山制药总厂的注射用头孢呋辛钠通过仿制药一致性评价，有利于提升该药品的市场竞争力。 ...

白云山(00874)公布，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药 品监督管理局签发的《药品补充申请批准通知书》。 白云山制药总厂注射用头孢呋辛钠于2006年5月在国内正式上市，并于2025年4月3日向国家药品监督管 理局递交一致性评价申请，于2025年4月11日获得受理。 头孢呋辛钠为第二代头孢菌素，对大多数革兰氏阴性菌、革兰氏阳性菌敏感，具有抗菌谱广、肾脏毒性 较低、对β内酰胺酶稳定的优势，临床广泛用于治疗唿吸道感染、泌尿系统感染及外科感染。注射用头 孢呋辛钠被列入国家基本药物目录(2018)，属于国家医保乙类品种(2025)。 白云山制药总厂的注射用头孢呋辛钠通过仿制药一致性评价，有利于提升该药品的市场竞争力。 ...

中国经济网12月22日讯 日前，河南省医药集中采购平台在其官网公示了三份药企公开致歉信。哈尔滨誉衡制药有限公司、吉林四环制药有限公司、珠海经 济特区粤康医药有限公司分别就各自涉及的不合规交易行为公开致歉。 吉林四环制药有限 吉林四环(2025) 016 号 公开致歉声明 我公司生产的产品"脑苷肌肤注射液",其合作 在不合规交易行为,违背了商业道德准则,扰乱了市 我们深表歉意! 事件发生后,我司高度重视,第一时间成立专I 商的全流程展开深入排查,严格落实与履行全链条1 行为坚决整改,并严肃追究相关人员责任,为彻底杜 生,我司已迅速制定并落实以下整改措施: 3. 加强合规体系建设:已系统性修订并强化了* 明确了违规行为的违约责任与处罚机制,并组织全f 伴进行专项培训与考核。 4. 解除涉及此事件相关人员的劳动合同。 我司郑重承诺:我们将以此为深刻的教训,举- 第二 壮信权益" 出空白 人击出 小人 小人 小 界的人，网 网 红 红 百 时 小 内 日 ， 上 叫 张 他 让 " 动 哈 生 - 决杜绝任何形式的不正当竞争行为,自觉维护医药则 为河南省乃至全国的医疗卫生事业健康发展贡献应2 我们再次为此次事件所造成 ...

Core Viewpoint - Yuyuan Pharmaceutical experienced a stock price decline of 2.08% on December 18, with a current price of 21.68 CNY per share and a market capitalization of 9.756 billion CNY [1] Financial Performance - For the period from January to September 2025, Yuyuan Pharmaceutical reported a revenue of 1.759 billion CNY, a year-on-year decrease of 41.20%, and a net profit attributable to shareholders of -148 million CNY, a year-on-year decrease of 170.56% [3] - The company has distributed a total of 1.092 billion CNY in dividends since its A-share listing, with 584 million CNY distributed over the past three years [4] Stock Market Activity - Yuyuan Pharmaceutical's stock has increased by 50.45% year-to-date, but has seen a decline of 19.23% over the last five trading days, 3.08% over the last 20 days, and 11.98% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on August 27, where it recorded a net buy of -105 million CNY [1] Shareholder Information - As of September 30, 2025, Yuyuan Pharmaceutical had 10,700 shareholders, a decrease of 8.39% from the previous period, with an average of 42,095 circulating shares per shareholder, an increase of 9.16% [3] - The top ten circulating shareholders include notable funds such as the Fortune Precision Medical Flexible Allocation Mixed A and the E Fund Healthcare Industry Mixed A, with changes in their holdings noted [4] Business Overview - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [2] - The revenue composition includes 55.67% from cardiovascular drugs, 20.88% from anti-infection drugs, and smaller percentages from other categories [2]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyuan New Asia Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its injectable drugs, Cefuroxime Sodium and Aztreonam, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Drug Approvals - The injectable Cefuroxime Sodium is indicated for infections caused by specific sensitive strains of microorganisms, including respiratory, ENT, urinary tract, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections, and postpartum and gynecological infections [1] - Cefuroxime Sodium was originally developed by GSK and launched in countries like the UK and Italy in 1978 [1] - The projected procurement amount for Cefuroxime Sodium injection in Chinese hospitals for 2024 is RMB 2.62 billion [1] Group 2: Aztreonam Details - Injectable Aztreonam is indicated for infections caused by sensitive Gram-negative bacteria, including urinary tract infections (both complicated and uncomplicated), lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1] - Aztreonam was developed by BMS and first launched in Italy in 1984 [1] - The projected procurement amount for Aztreonam injection in Chinese hospitals for 2024 is RMB 163 million [1]

Group 1: Company Announcements - ChaoYing Electronics' wholly-owned subsidiary plans to invest 1.468 billion RMB in an AI computing high-end printed circuit board expansion project in Thailand, aiming to enhance its product layout in high-end PCB applications such as routers and AI servers [1] - DeMingLi is in the process of planning a refinancing matter, which is still in the internal communication stage without a clear plan or determined financing amount [1] - *ST YuanCheng's stock has triggered mandatory delisting due to a market capitalization below 500 million RMB for 20 consecutive trading days, leading to a suspension of trading starting November 11, 2025 [1] Group 2: Investment and Cooperation - ZhongBei Communication signed a framework agreement for comprehensive computing services worth 1 billion RMB with Hongxin Electronics, with a service period of 60 months [2] - ShangTai Technology plans to invest approximately 4.07 billion RMB in a project to produce 200,000 tons of lithium-ion battery anode materials in Shanxi Province [3] Group 3: Clinical Trials and Approvals - Maiwei Bio's innovative drug 9MW3811 injection for pathological scars has received approval for a Phase II clinical trial, with plans to start by the end of 2025, positioning it as the first IL-11 targeted drug in this indication [3]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its generic drugs, injectable Cefuroxime Sodium and injectable Aztreonam, confirming their quality and efficacy consistency [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyuan New Asia Pharmaceutical Co., Ltd., has been granted a Supplementary Drug Application Approval Notice [1] - The injectable Cefuroxime Sodium is indicated for treating infections caused by specific strains of microorganisms in respiratory, ENT, and urinary tract infections, first launched in 1978 in countries like the UK and Italy [1] - The injectable Aztreonam is used for treating urinary tract infections (both complex and uncomplicated) and lower respiratory tract infections caused by sensitive Gram-negative bacteria, first launched in Italy in 1984 [1]